Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 805-813

  Hamberg, Paul ^a,d   Woo, Margaret M ^b   Chen, Lin Chi ^c   Verweij, Jaap ^a   Porro, Maria Grazia ^b   Zhao, Lily ^b   Li, Wenkui ^b   Van Der Biessen, Diane ^a   Sharma, Sunil ^c   Hengelage, Thomas ^b   De Jonge, Maja ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NEVADA CANCER INSTITUTE   (United States)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

CYP3A; Histone deacetylase inhibitor; LBH589; Panobinostat

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DOXAZOSIN; HISTONE DEACETYLASE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; PANOBINOSTAT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PANCREAS CANCER; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SALIVARY GLAND CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VOMITING;

ADULT; AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYPOPHOSPHATEMIA; KETOCONAZOLE; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; SAMPLE SIZE;

EID: 80054703794     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1693-x     Document Type: Article

References (17)

1. O Khan NB La Thangue 2008 Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas Nat Clin Pract Oncol 5 714 726 18839006 10.1038/ncponc1238 1:CAS:528:DC%2BD1cXhsVais7%2FO
2. O Witt HE Deubzer T Milde I Oehme 2009 HDAC family: what are the cancer relevant targets? Cancer Lett 277 8 21 18824292 10.1016/j.canlet.2008.08.016 1:CAS:528:DC%2BD1MXjtFOhsL4%3D
3. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 16955068 10.1038/nrd2133 1:CAS:528:DC%2BD28XptVCltrY%3D
4. P Atadja 2009 Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Cancer Lett 280 233 241 19344997 10.1016/j.canlet. 2009.02.019 1:CAS:528:DC%2BD1MXmsF2jtL4%3D
5. L Ellis Y Pan GK Smyth, et al. 2008 Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma Clin Cancer Res 14 4500 4510 18628465 10.1158/1078-0432.CCR-07-4262 1:CAS:528:DC%2BD1cXosFGitL0%3D
6. Ottman OG, Spencer A, Prince HM et al (2008) Phase IA/II study of oral panobinostat (LBH589): a novel pan-deacetylase inhibitor demonstrating efficacy in patients with advanced hematologic malignancies. In: Proceedings of the Annual Meeting American Society Hematology; abstract 958
7. 14C]-panobinostat. In: Proceedings of the Annual Meeting American Society Oncology; abstract # 2549
8. T Shimada H Yamazaki M Mimura, et al. 1994 Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 414 423 8035341 1:CAS:528: DyaK2cXlt1OmtL4%3D
9. SA Julious 2005 Sample size of 12 per group rule of thumb for a pilot study Pharm Stat 4 287 291 10.1002/pst.185
10. PC O'Brien TR Fleming 1975 A multiple testing procedure for clinical trials Biometrics 35 549 556 10.2307/2530245
11. HM Prince MJ Bishton RW Johnstone 2009 Panobinostat (LBH589): a potent pan-deaceylase inhibitor with promising activity against hematologic and solid tumors Futur Oncol 5 601 612 10.2217/fon.09.36 1:CAS:528:DC%2BD1MXnt1GjtrY%3D
12. M Dickinson D Ritchie DJ Deangelo, et al. 2009 Preliminary evidence of the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma Br J Haematol 147 97 101 19663825 10.1111/j.1365-2141.2009.07837.x 1:CAS:528:DC%2BD1MXhtlWltbbF
13. Prince HM, George D, Patnaik A, et al. (2007) Phase I study of oral LBH589: a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. In: Proceedings of the Annual Meeting American Society Clinicology; abstract # 3500
14. M Shou M Hayashi Y Pan, et al. 2008 Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction Drug Metab Dispos 36 2355 2370 18669588 10.1124/dmd.108.020602 1:CAS:528:DC%2BD1cXhtlWiu77F
15. BS Mann JR Johnson MH Cohen, et al. 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 1247 1252 17962618 10.1634/theoncologist.12-10-1247 1:CAS:528:DC%2BD2sXhtlOmurrL
16. S Subramanian SE Bates JJ Wright I Espinoza-Delgado RL Piekarz 2010 Clinical toxicities of histone deacetylase inhibitors Pharmaceuticals 3 2571 2767 10.3390/ph3092751
17. L Gore ML Rothenberg CL O'Bryant MK Schultz AB Sandler D Coffin C McCoy A Schott C Scholz SG Eckhardt 2008 A phase I and pharmocokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas Clin Cancer Res 14 4517 4525 18579665 10.1158/1078-0432. CCR-07-1461 1:CAS:528:DC%2BD1cXosFGitLs%3D